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326Objectives: The appropriate management of aortic intramural hematoma is still controversial, because a variety
of aortic events can arise during follow-up in some patients. However, simplified identification of these patients
remains challenging. The present study aimed to determine the prognostic significance of serial C-reactive
protein measurements for the prediction of adverse events in patients with acute aortic intramural hematoma.
Methods:A total of 180 patients with aortic intramural hematomawere retrospectively reviewed. The C-reactive
protein data were obtained at admission and 2 days, 1 week, and 2 weeks from the onset, and the maximum value
was obtained during the acute phase. Adverse aorta-related events were defined by a composite of aortic rupture,
aortic aneurysm, and surgical or endovascular aortic repair.
Results: The C-reactive protein value was 3.0 4.6, 8.7 5.9, 9.0 5.5, and 5.7 4.5 mg/dL on admission and
2 days, 1 week, and 2 weeks from the onset, respectively. The maximal value of C-reactive protein was
12.4  6.3 mg/dL at a mean of 4 days from the onset. Patients with elevated C-reactive protein levels (7.2
mg/dL) at 2 weeks had significantly greater rates of aorta-related events (P<.001). On multivariate analysis,
an elevated C-reactive protein level at 2 weeks (hazard ratio, 3.16; P< .001) and the development of an
ulcer-like projection (hazard ratio, 2.68; P¼ .002) were independent predictors of adverse aorta-related events.
In addition, an elevated C-reactive protein level at 2 weeks had incremental value compared with the develop-
ment of an ulcer-like projection (chi-square, 16.94 for ulcer-like projection only vs 34.32 with the addition of
C-reactive protein at 2 weeks, P<.001).
Conclusions: C-reactive protein was a simple and useful marker providing incremental prognostic information
compared with the development of an ulcer-like projection in patients with aortic intramural hematoma.
(J Thorac Cardiovasc Surg 2014;147:326-31)Aortic intramural hematoma (IMH) has been recognized as
a unique disease with pathologic and clinical features that
differ from those of classic aortic dissection (AD).1,2 IMH
is often successfully managed by medical therapy, with
lower mortality and morbidity rates than with classic
AD.3-6 However, a variety of aortic events can arise
during follow-up in some patients. Although several imag-
ing features, such as an ulcer-like projection (ULP), have
been reported to be used to identify these high-risk pa-
tients,4,7-10 simplified identification of these patients
remains challenging.
Acute aortic syndrome is associated with a systemic ac-
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The Journal of Thoracic and Cardiovascular Surgin inflammatory markers, including C-reactive protein
(CRP).11-15 These elevated serologic markers can be
caused by the underlying disease or the acute aortic
pathologic entity itself. Recently, elevated serum CRP
levels were reported to be associated with an adverse
outcome in patients with classic AD.14,15 However, few
data are available for patients with IMH regarding the
association between CRP levels and clinical outcomes.
The present study aimed to determine the prognostic
significance of serial CRP measurements for predicting
adverse clinical events in patients with IMH.METHODS
Patient Characteristics
We retrospectively reviewed the data from 180 patients, whowere diag-
nosed with IMH within 48 hours from the onset, from January 1994 to
March 2011 and for whom serial data for CRP within 2 weeks after onset
and follow-up clinical data were available. We excluded patients who un-
derwent emergency or urgent surgical or endovascular repair during the
acute phase. Therefore, for type A IMH, we only included those patients
who had a stable course with medical therapy only. Patients with type A
IMH were treated as previously reported.5 Emergent surgery was per-
formed in the case of complications, such as cardiac tamponade. Other-
wise, supportive medical therapy was given initially, with tight blood
pressure control. Timed surgery was performed in the case of disease pro-
gression, such as the development of an ULP in the ascending aorta. Theery c January 2014
Abbreviations and Acronyms
AD ¼ aortic dissection
CRP ¼ C-reactive protein
CT ¼ computed tomography
IMH ¼ intramural hematoma
MDCT ¼ multidetector CT
ULP ¼ ulcer-like projection
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Ddiagnoses were established by contrast-enhanced computed tomography
(CT) and confirmed by transesophageal echocardiography when the diag-
nosis by CTwas inconclusive. IMH was defined as a crescentic or circular
high-attenuation area along the aortic wall without contrast enhancement
on the CT scan and regional aortic wall thickening on the transesophageal
echocardiogramwithout evidence of direct flow communication. The insti-
tutional review board approved the present study.
CRP Measurement
TheCRP dataweremeasured at admission and 2 days, 1 week (6-8 days),
2 weeks (13-15 days) from the onset of IMH, and the maximal value during
the acute phasewas recorded. These datawere retrospectively obtained from
themedical records.CRPwasmeasured by latex agglutination nephelometry
(IatroCRP-Ex,MitsubishiChemicalMedience, Tokyo, Japan) using an auto-
analyzer (Hitachi7600, Hitachi, Tokyo, Japan). Because we have routinely
measured CRP levels during hospitalization in patients with acute IMH,
no patients had unavailable CRP data during the acute phase.
Clinical Follow-up and CT Evaluation
The mean follow-up period was 5.1  3.9 years. Adverse aorta-related
events were defined by a composite of aortic rupture, aortic enlargement
(60 mm), and surgical or endovascular aortic repair. The development
of an ULP was assessed by comparing the initial and follow-up CT images.
An ULP was defined as a localized blood-filled pouch protruding into the
thrombosed false lumen, as previously described.7,8 All images and
diagnoses were reassessed by 2 experienced readers (K.K. and S.K.)
according to current knowledge.
Statistical Analysis
The categorical variables are reported as numbers and percentages and
were compared using the chi-square test or Fisher’s exact test, as appropri-
ate. Continuous variables are reported as themean standard deviation and
were compared using unpaired t tests. Because of the skewed distribution of
CRP and thewhite blood cell count, a nonparametric test (Mann-WhitneyU
test) was used to compare the values between the groups. A nonparametric
repeated-measures analysis of variance (Friedman test) was used to test sta-
tistical differences in the CRP values with time among the groups, and the
Wilcoxon signed-rank test was used to test statistical differences between
each time group. Survival analysis was performed using Kaplan-Meier
analysis, and differences in survival between the groups were examined
with the log-rank test. To determine the predictors for adverse aorta-
related events during the follow-up period, the Cox proportional hazards
model was used to estimate the risk of the following potential variables:
age, gender, Stanford type, hypertension, diabetesmellitus, hyperlipidemia,
ischemic heart disease, previous stroke, renal insufficiency (defined as es-
timated glomerular filtration rate<60 mL/min/1.73 m2), chronic obstruc-
tive pulmonary disease, development of an ULP, and high CRP levels at
2 weeks from onset. Those variables for which the probability values
were<.20 on univariate analyses and for which the proportionality assump-
tions were generally fair were included in the multivariate analysis. The
multivariate Cox proportional hazard model was built by stepwise variable
selection with entry and removal exit criteria set at P ¼ .05 and P ¼ .10,The Journal of Thoracic and Carespectively. For additional comparison of the prognostic value of CRP
and to determine the cutoff values, receiver operating characteristics curves
were generated, and the area under the curves was calculated.
An incremental prognostic value was defined as a significant increase in
theWald statistic and likelihood ratio tests after the addition of CRP data to
an optimized Cox model of ULP data alone. Incremental prognostic value
was considered to be present for any of these steps when a significant in-
crease in Wald global chi-square value was found. The C-statistics index
was also calculated to assess the model discrimination, the ability of the
model to correctly identify with respect to aorta-related events. The Harrell
C-index was the primary measure of discrimination.16 The increased dis-
criminative value of the CRP level, in addition to the previously docu-
mented value of the development of ULP, was further examined using
the method described by Pencina et al.17
All analyses were performed with SPSS software, version 17.0 (SPSS,
Chicago, Ill), and R, version 2.3.1 system (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
Overall Patient Characteristics and Clinical
Outcomes
Of the 180 patients, 101 were men and 79 were women,
with a mean age of 70  11 years. Of the 180 patients, 40
were diagnosed with Stanford type A IMH and 140 with
type B IMH. All patients, including those with type A IMH,
were treated medically, as previously reported.5,8 All study
patients underwent follow-up CT, and the mean duration be-
tween admission and the follow-up CT scan was 30  42
days. In addition, the duration between admission and the
last follow-upCTscanwas 3.6 3.8 years.Themeannumber
ofCT scans per patientwas 7.4.During follow-up, 49patients
had adverse aorta-related events. Of these patients, 8 died of
aortic rupture (2 patients with an initial diagnosis of type A
IMH and 6with typeB IMH), 23 underwent surgical or endo-
vascular aortic repair (4 for repeat dissection of the ascending
aorta, 16 for aortic aneurysm, defined as60mm for the tho-
racic aorta or50 mm for the abdominal aorta, and 3 for im-
pending rupture), and 18 had significant aortic dilatation
without surgery (defined as 60 mm for the thoracic aorta
or 50 mm for the abdominal aorta). The clinical features
of the patients with aorta-related events and those without
these events are listed in Table 1.Time Course Change in CRP Levels
Figure 1, A shows the time course change in CRP levels.
Themean CRP level on admission and 2 days, 1 week, and 2
weeks from onset was 3.0  4.6, 8.7  5.9, 9.0  5.5, and
5.7  4.5 mg/dL, respectively. The maximum CRP value
was 12.4  6.3 mg/dL at 4  2 days from onset. The max-
imal diameter of the ascending aorta, maximal hematoma
thickness, and peak CRP value of the 40 patients with
type A IMH was 46.0  4.3 mm, 9.6  3.4 mm, and
14.0  6.7 mg/dL, respectively. No significant correlations
were found between the peak CRP level and maximal diam-
eter of the ascending aorta or maximal hematoma thickness
in these stable patients.rdiovascular Surgery c Volume 147, Number 1 327
TABLE 1. Patient characteristics
Characteristic
Aortic event
P
value
Yes
(n ¼ 49)
No
(n ¼ 131)
Age (y) 71  8 69  11 .19
Men (n) 27 (55) 74 (57) .87
Stanford type .72
A 10 30
B 39 101
Hypertension (n) 43 (88) 113 (86) .79
Diabetes mellitus (n) 9 (18) 31 (24) .45
Hyperlipidemia (n) 20 (41) 45 (34) .42
Smoking (n) 20 (41) 43 (33) .32
Previous stroke (n) 10 (20) 18 (14) .27
Ischemic heart disease (n) 3 (6) 14 (11) .27
Renal insufficiency (n) 27 (55) 78 (60) .59
COPD (n) 1 (2) 1 (1) .47
Antihypertensive therapy (n)
Calcium antagonist 44 (90) 115 (88) .71
b-Blocker 45 (92) 112 (86) .26
ACEI/ARB 23 (47) 66 (50) .68
Systolic BP at first follow-up visit
120 mm Hg 20 (41) 54 (41) .96
121-140 mm Hg 19 (39) 49 (37) .87
>140 mm Hg 7 (14) 20 (15) .87
Development of ULP (n) 35 (71) 32 (24) <.001
CRP level (mg/dL)
On admission 4.7  5.6 2.4  4.0 .008
2 days from onset 11.4  6.2 7.9  5.6 .002
1 week from onset 11.3  5.7 8.1  5.2 .001
2 weeks from onset 8.8  5.2 4.5  3.6 <.001
Maximal value 15.4  6.0 11.3  6.1 <.001
WBC measurement (3103 count/mm3)
On admission 10.2  3.6 10.4  3.9 .76
2 days from onset 10.1  3.5 9.7  3.4 .36
1 week from onset 8.6  3.0 7.6  2.4 .04
2 weeks from onset 7.6  2.5 7.2  2.4 .23
Maximal value 11.8  3.7 11.6  4.1 .70
COPD, Chronic obstructive pulmonary disease; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure;
ULP, ulcer-like projection; CRP, C-reactive protein; WBC, white blood cell.
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a great effect on the CRP levels, we excluded 25 patients (22
with type A IMH and 3 with type B IMH) who had under-
gone surgical intervention within 2 weeks from onset. The
mean interval from symptom onset to intervention for those
patients was 1.4 days, and the mean CRP value at interven-
tion was 8.8  7.9 mg/dL.
The patients with aorta-related events had significantly
greater CRP levels than those without aorta-related events
on admission and 2 days, 1 week, and 2 weeks from onset
and greater maximal CRP levels (Table 1 and Figure 1, B).New ULP Development
Of the 180 study patients, 67 showed newly developed
ULP on the follow-up CT images. The mean interval to328 The Journal of Thoracic and Cardiovascular Surgthe diagnosis of ULP development from the onset of symp-
toms was 24 days (range, 6-90 days). At more than 3months
of follow-up, no patients showed newULP development. Of
the 40 patients with type A IMH, 12 showed an ULP at the
aortic arch or descending aorta, and only 1 patient had an
ULP at the ascending aorta. Patients with newly developed
ULP had greater CRP levels at 2 weeks from onset
(7.5  5.0 vs 4.6  3.8 mg/dL, P< .001) and greater
peak CRP levels (14.2  6.3 vs 11.4  6.1 mg/dL,
P ¼ .007) than those without an ULP.
Predictors of Adverse Aorta-Related Events
Receiver operating characteristics curve analysis identi-
fied a CRP level of 7.2 mg/dL or more at 2 weeks from onset
as a cutoff for predicting future aorta-related events (area
under the curve, 0.76; 95% confidence interval, 0.68-
0.84; P< .001) with sensitivity, specificity, and positive
and negative predictive value of 63%, 80%, 54%, and
85%, respectively. Patients with elevated CRP levels
(7.2 mg/dL) at 2 weeks had significantly greater rates of
aorta-related events than those with CRP levels less than
7.2 mg/dL (P< .001, Figure 2, A). Similarly, peak CRP
levels of 12.0 mg/dL or greater (area under the curve,
0.68; 95% confidence interval, 0.59-0.76; P< .001) was
identified as a cutoff value, with a sensitivity, specificity,
and positive and negative predictive value of 73%, 56%,
43%, and 85%, respectively.
The results of the univariate and multivariate analyses for
the predictors of adverse aorta-related events are listed in
Table 2. A CRP level of 7.2 mg/dL or more at 2 weeks from
theonset of IMHand thedevelopment ofULPwere confirmed
as the strongest independent predictors of aorta-related
events. In addition, the incremental value of CRP over the de-
velopment of ULP was determined using the following sur-
vival models: model 1, which incorporated ULP only;
model 2, which incorporated ULP and the maximal CRP
value; and model 3, which incorporated ULP and CRP at 2
weeks from the onset of IMH (Table 3). Model 3 revealed
a significantly greater increased chi-square andC-statistic, in-
dicating that elevated CRP levels at 2 weeks had incremental
value over the development of ULP (Table 3).
Figure 2, B shows the aorta-related event-free survival
among the 4 subgroups, classified by both CRP level at 2
weeks from the onset of IMH and the development of
ULP. Concomitance of elevated CRP levels and ULP was
associated with a poor prognosis among the groups.
DISCUSSION
The present study reports the clinical usefulness of se-
rial CRP measurement for identifying high-risk patients
with IMH. The main findings of the present study were
as follows: elevated CRP levels (7.2 mg/dL) at 2 weeks
from the onset of IMH were independently associated with
adverse aorta-related events; and CRP measurementery c January 2014
FIGURE 1. Kinetics of release of C-reactive protein (CRP) levels in patients with intramural hematoma. A, Time course change in mean CRP levels in all
study patients with acute aortic intramural hematoma. Error bars indicate standard error of the mean. *P<.001 compared with CRP level on admission.
B, Comparison of time course change in mean CRP levels and standard error of the mean in patients with intramural hematoma with and without adverse
aorta-related events. Error bars indicate standard error of the mean. *P<.01 and yP<.001 compared with patients without aorta-related events.
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development of ULP.
CRP is an acute-phase reactant that reflects different
degrees of inflammation and systemic stress and is a simple
marker widely available for clinical use. CRP has been
identified as an independent risk factor for a variety of
cardiovascular diseases.18-21 Recently, an inflammatory
mechanism has been shown to be involved in medial
degeneration, with an association with clinical
manifestations of acute aortic syndrome.11,13 Additionally,
inflammatory processes play a pathophysiologic role in
the development and progression of aortic disease.8 CRPFIGURE 2. Interval to adverse aorta-related event in patients with intramural h
with (A) C-reactive protein (CRP) of 7.2mg/dL or more at 2 weeks from onset an
than 7.2 mg/dL without ulcer-like projection (ULP), CRP less than 7.2 mg/dL w
morewith ULP. *P<.001 compared with CRP less than 7.2 mg/dL without ULP,
ULP, respectively. Adverse aorta-related events included aortic rupture, aortic
The Journal of Thoracic and Cais inevitably elevated in patients with acute aortic syn-
drome. Furthermore, it has been reported that elevated
CRP levels are associated with adverse aortic events in pa-
tients with classic AD.14,15 The present study demonstrated
that CRP levels peaked within 1 week and consistently
elevated CRP levels during the acute phase were
associated with poor clinical outcomes in patients with
IMH. The possible explanation for why the elevated CRP
levels had prognostic information in patients with IMH is
that the CRP levels might represent the extent of
inflammatory reaction in the involved aorta and reflect the
damage to the lesion of the aortic wall. Several previousematoma. Comparison of aorta-related event-free survival curve in patients
d thosewith CRP less than 7.2mg/dL and (B) among 4 subgroups: CRP less
ith ULP, CRP of 7.2 mg/dL or more without ULP, and CRP of 7.2 mg/dL or
CRP less than 7.2 mg/dL with ULP, and CRP of 7.2 mg/dL or morewithout
surgery, and significant aortic aneurysm without surgery.
rdiovascular Surgery c Volume 147, Number 1 329
TABLE 2. Univariate and multivariate analysis of predictors of
adverse aorta-related events
Variable
Univariate
predictors
Multivariate
predictors
HR
(95% CI)
P
value*
HR
(95% CI)
P
value*
Age (>75 y) 1.47 (0.82-2.63) .19 — —
Men 0.71 (0.41-1.26) .24 — —
Stanford type A 0.73 (0.36-1.46) .37 — —
Development of ULP 3.45 (1.84-6.44) <.001 2.68 (1.42-5.07) .002
CRP  7.2 mg/dL at
2 wk
3.89 (2.18-6.97) <.001 3.16 (1.74-5.73) <.001
Hypertension 0.93 (0.39-2.19) .87 — —
Diabetes mellitus 0.84 (0.41-1.73) .64 — —
Hyperlipidemia 1.46 (0.82-2.58) .20 — —
Ischemic heart disease 0.86 (0.27-2.79) .81 — —
Previous stroke 1.43 (0.71-2.89) .32 — —
Renal insufficiency 1.03 (0.72-1.47) .89 — —
COPD 1.66 (0.09-7.56) .64 — —
HR,Hazard ratio;CI, confidence interval;ULP, ulcer-like projection;CRP,C-reactive
protein; COPD, chronic obstructive pulmonary disease. *Cox proportional hazard
model analysis.
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Dstudies have suggested that inflammation exists in the
involved aorta in patients with classic AD.11,13,14 Our
findings suggest that inflammation of the involved aorta is
present in those with IMH just as in those with classic AD
and that a severely damaged aortic wall might be more
prone to lead to adverse aorta-related events.
In the present study, the CRP levels in patients with aorta-
related events increased to greater peak values and had
sustained elevation at 2 weeks than in those without aorta-
related events. These sustained greater CRP levels might
be indicative of residual inflammation of the localized le-
sion, such as new intimal disruption, which leads to the de-
velopment of ULP. ULP has been reported to be strong
predictor of adverse aorta-related events in patients with
IMH.4,7,8 In the present study, patients with the new
development of an ULP also had greater CRP levels at 2
weeks from the onset of IMH than those without an ULP.
Thus, elevated CRP levels might be partially associated
with an ulcerative lesion of the involved aorta, another
possible explanation of why CRP levels are associatedTABLE 3. Incremental value of different measurement points of CRP ove
Variable HR (95% CI) P value* Chi-squ
Model 1 16.94
ULP 3.45 (1.84-6.44) <.001
Model 2 24.68
ULP 2.81 (1.48-5.33) .002
Peak CRP 2.45 (1.28-4.70) .007
Model 3 34.32
ULP 2.68 (1.42-5.07) .002
CRP at 2 wk 3.16 (1.74-5.73) <.001
HR, Hazard ratio; CI, confidence interval; ULP, ulcer-like projection; CRP, C-reactive pro
330 The Journal of Thoracic and Cardiovascular Surgwith adverse events in patients with IMH. However, the
results of the present study demonstrated that elevated
CRP values could provide incremental prognostic
information over the development of an ULP in patients
with IMH. Therefore, only development of an ULP or
ulcerative lesion in the involved aorta cannot explain the
relationship between the elevated CRP levels and poor
clinical outcomes.
In the present study, the peak CRP levels and CRP levels
at 2 weeks after onset in patients with IMH had significant
prognostic information. Sakakura and colleagues14 demon-
strated that peak CRP values are associated with long-term
outcomes in patients with classic AD. In our patients with
IMH, although the peak CRP levels were also associated
with adverse aorta-related events, the CRP levels at 2 weeks
provided better prognostic value. This finding suggests that
the healing process of aortic pathologic features might pro-
vide more important prognostic information than the sever-
ity of aortic inflammation in patients with IMH. Additional
investigations are necessary to elucidate the precise mech-
anism of the association between elevated CRP levels and
adverse clinical events.Study Limitations
The present study had several limitations that should be
acknowledged. First, we included patients with type A
IMH, who might be supposed to have different clinical
courses than patients with type B IMH. However, we ex-
cluded those with type A IMH who underwent emergency
surgery because of complications or timed surgery because
of progression in the ascending aorta during the acute phase.
Thus, the Stanford type did not significantly affect the out-
come in the present study. Second, we diagnosed the disease
using axial CT and, partly, transesophageal echocardiogra-
phy, from both of which the presence of ULP could have
been overlooked.22 In addition, the timing of the follow-
up CT scan might have affected the detection of ULP devel-
opment. Earlier follow-up CT studies might have missed
ULP development. Furthermore, the size of the ULP was
not assessed in the present study. This was because a limited
number of patients underwent multidetector CT (MDCT).
A previous study reported that MDCT was recommendedr ULP
are P value C statistic (95% CI) P value
Reference 0.644 (0.565-0.723) Reference
.004 0.700 (0.622-0.778) .040
<.001 0.710 (0.621-0.800) <.001
tein. *Cox proportional hazard model analysis.
ery c January 2014
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height of the small intimal defect in the entire aorta.22 It
might be difficult to evaluate the precise ULP size without
using MDCT. Additional studies with MDCT are required
to investigate the relationship between the radiographic fea-
tures of ULP and the prognosis of patients with IMH. Third,
CRP is a nonspecific inflammatory marker; it reflects, not
only the extent of the aortic dissection itself, but also con-
comitant inflammatory disease such as pneumonia. Finally,
we did not include the aortic diameter and hematoma thick-
ness as variables to predict aorta-related events. In the pres-
ent study, most of the study patients had type B IMH, with
a maximal diameter that varied depending on the portions of
the affected aorta. Furthermore, we excluded patients with
type A IMH who had undergone surgical intervention
within 2 weeks of the onset of IMH. It would be difficult
to regard measures of the different portions of the diseased
aorta as the same predictive variable.A
C
DClinical Implications
It has been reported that patients with newly developed
ULP should be carefully followed up with frequent imaging
studies, because the ULP frequently progresses.7,8 Risk
stratification of IMH has been established using only
imaging modalities. However, frequent CT can lead to
excessive radiation and contrast exposure. From our data,
the serum CRP level is a simpler and less-invasive marker
for identifying high-risk patients, and it might reduce the
necessity for follow-up CT examinations.
In addition, our results suggest that sustained high CRP
levels might represent residual aortic inflammation, leading
to future aorta-related events. Anti-inflammatory or anticy-
tokine therapy might have a possible role in reducing future
aorta-related events, especially in patients with elevated
CRP levels.12References
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